发明名称 |
GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS |
摘要 |
Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Methods of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes, and methods of treating a patient diagnosed with HCC or breast cancer by administering an agent that alters expression or activity of one or more of the disclosed tumor-associated genes, are described. |
申请公布号 |
US2014220043(A1) |
申请公布日期 |
2014.08.07 |
申请号 |
US201414252005 |
申请日期 |
2014.04.14 |
申请人 |
The United States of America, as represented by the Secretary, Department of Health and Human |
发明人 |
Wang Xin Wei;Roessler Stephanie K. |
分类号 |
C07K16/18;C12N15/85;C12N15/86;C12N15/113 |
主分类号 |
C07K16/18 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating HCC or breast cancer in a subject, comprising administering to the subject a therapeutically effective amount of an agent that alters expression or activity of at least one tumor-associated molecule selected from the group consisting of SH2D4A, CCDC25, ELP3, SORBS3, HNRPD, PAQR3, PHF17 and DCK. |
地址 |
Bethesda MD US |